Podcasts about Poolbeg

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce a significant milestone in the company's clinical development strategy: the U.S. Food and Drug Administration has granted Orphan Drug Designation to POLB 001, Poolbeg's innovative oral therapy aimed at preventing Cytokine Release Syndrome caused by T-cell engager bispecific antibody immunotherapies. POLB 001, an oral small molecule inhibitor of the IL-1 receptor, is designed to modulate the inflammatory response without suppressing the underlying anti-cancer immune activation. The FDA's Orphan Drug Designation recognizes the potential of POLB 001 to address a rare but serious medical condition, affecting fewer than 200,000 individuals annually in the United States. This designation confers a range of developmental and commercial incentives including seven years of U.S. market exclusivity post-approval, waiver of certain FDA fees, such as the Prescription Drug User Fee Act or PDUFA application fees and others. The company plans to initiate a Phase 2a clinical trial in the second half of 2025, marking the next step in evaluating POLB 001's efficacy and safety in a controlled setting. Poolbeg anticipates completing interim analysis in the first half of 2026, with topline data expected in the second half of 2026. With the Orphan Drug Designation in hand, Poolbeg is now well-positioned to advance discussions with potential partners and stakeholders as it progresses toward its clinical milestones. #proactiveinvestors #poolbegpharma #aim #polb #OrphanDrug #POLB001 #FDAApproval #CytokineReleaseSyndrome #CancerTherapy #BiotechNews #Immunotherapy #ClinicalTrials #PharmaInvesting

Watch on YouTube Vox Markets caught up with Poolbeg Pharma #POLB CEO Jeremy Skillington at the Master Investor Show, where he discussed the company's exciting progress in 2024. Jeremy highlighted strong investor engagement and shared updates on Poolbeg's two lead programmes.

Following their H1 interims for 2024, Vox Markets talks to their CEO Jeremy Skillington

Poolbeg Pharma CEO Jeremy Skillington joined Steve Darling from Proactive to announce the company's unaudited interim results for the first half of 2024, highlighting strong progress with its lead development candidate, POLB 001. As of 30 June 2024, the company reported a cash balance of £10.1 million, showcasing its prudent financial management and ability to support ongoing development initiatives. Skillington emphasized that POLB 001 is on track, with robust data demonstrating its efficacy in reducing cancer immunotherapy-induced cytokine release syndrome (CRS) in an in vivo animal model. This strengthens the company's patent portfolio, with the U.S. Patent Office recently granting Poolbeg a new patent for its Immunomodulator II, covering a class of drugs, including POLB 001, aimed at treating or preventing hypercytokinemia (cytokine storm) across a range of diseases. This patent approval enhances Poolbeg's ability to expand its intellectual property and attract potential partners. Poolbeg Pharma is actively engaging with multiple potential partners to further develop and commercialize POLB 001. Additionally, the company signed an exclusive 12-month option agreement for tPTX, a novel topical muco-adherent treatment for oral ulcers in patients suffering from Behçet's Disease. The treatment holds significant potential, with FDA Fast Track Designation, Orphan Drug Designation, and a possible 505(b)(2) approval pathway in the U.S., indicating its promising market prospects. Skillington emphasized Poolbeg's commitment to advancing its pipeline while maintaining strong financial discipline, positioning the company for future growth and partnerships in the biotech sector. #proactiveinvestors #poolbegpharma #aim #polb #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #RareDiseases #JeremySkillington #GLP1Receptor #CancerImmunotherapy #PharmaNews #ClinicalTrials #FDAApproval #ProactiveInvestors

John, sailing enthusiast and Commodore of the Irish Cruising Association told Brendan all about the annual Three Bridges Rally. It's when three of the bridges on the Liffey will open and lift - allowing a parade of some 45 boats to sail up-river from Poolbeg up to the Matt Talbot bridge. It's on at 3pm on the 7th of September.

Painting work on the Poolbeg Chimneys in Dublin begins this week. Having been immortalised in print, on t-shirts and even coffee mugs, why are the towers so iconic, and do they continue to divide opinion?Joining guest host Mairead Ronan to discuss is Emma Gileece, Architectural Historian.

Painting work on the Poolbeg Chimneys in Dublin begins this week. Having been immortalised in print, on t-shirts and even coffee mugs, why are the towers so iconic, and do they continue to divide opinion?Joining guest host Mairead Ronan to discuss is Emma Gileece, Architectural Historian.

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Pour écouter l'émission en entier, sans pub, abonnez-vous ! https://m.audiomeans.fr/s/S-tavkjvmo Pendant plus de deux siècles, plusieurs milliers de jeunes femmes irlandaises sont envoyées dans des institutions censées leur donner une éducation et un savoir-faire conformes aux valeurs conservatrices et religieuses prônées par la société. Mais la réalité est toute autre. Loin des promesses de vivre à l'écart des maux du monde extérieur, ces filles sont en réalité contraintes au travail forcé et aux maltraitance des religieuses. Et dès les années 1990, de nombreuses victimes des couvents de la Madeleine témoignent des violences subies pendant plusieurs années, ce qui nous permet d'avoir connaissance de cette invraisemblable histoire pourtant réelle. Bibliographie : - Maeve O'Rourke, Ireland's Magdalene Laundries and the state's duty to protect. Hibernian Law Journal, 2011. - Maria Luddy, Cliona Murphy, Women surviving, studies in Irish Women's History in the 19th and 20th centuries. Poolbeg, 1989. - Susan Mumm, 'Not worse than other girls': the convent-based rehabilitation of fallen women in Victorian Britain. Journal of Social History, 1996. pp. 527–547 Documentaire : Sex in a cold climate (1998), réalisé par Steve Humphries Rapport de la Commission interministérielle chargée d'établir les faits de l'implication de l'État dans les Laveries de la Madeleine, Ministère de la justice - Sénateur Martin McAleese, octobre 2020. Film : The Magdalen sisters, de Peter Mullan (2002)

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using human viral challenge data Headquartered in London and publicly traded on the London Stock Exchange & the OTC Markets in the US AIM: POLB | OTCQB: POLBF Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines that address critical unmet medical needs. They are focused on strategically commercialising approved and marketed drugs to fund the development of a robust pipeline of innovative products, driving significant value creation. Jeremy Skillington began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech, he was responsible for executing over 40 licencing, investment and collaboration transactions.  Returning to Ireland in 2009, Jeremy led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd. In 2014 Jeremy joined German investment fund HS Lifesciences GmbH to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH. Jeremy joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September 2020 for €380M (£325M) upfront and significant downstream milestones.  Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D.  He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck. https://www.share-talk.com/poolbeg-pharma-plc-chief-executive-officer-jeremy-skillington-phd-talking-to-zak-mir/

Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD and Chief Business Officer, David Allmond present an overview of their current programmes and opportunities, focussing on POLB 001, their oral delivery platforms, exclusive option agreement and their AI-powered research using human viral challenge data, followed by a Q&A session. Jeremy Skillington PhD, Chief Executive Officer 00:16 - Introduction 03:06 - Programmes 04:08 - 2024 highlights David Allmond, Chief Business Officer 05:03 - POLB 001 & CRS 08:01 - POLB 001's efficacy 10:15 - POLB 001 Market Opportunity 14:17 - POLB 001 support 16:12 - Topical PTX & Behçet's Disease 18:36 - Topical PTX 12 month option 20:29 - Topical PTX Phase 2 trial Jeremy Skillington PhD, Chief Executive Officer 22:05 - Topical PTX outlook 22:48 - Oral delivery platform 25:02 - Artificial Intelligence programmes 28:13 - Investment case 29:30 - Q&A Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. For more information, please go to www.poolbegpharma.com  or follow on Twitter and LinkedIn @PoolbegPharma.

WAKE gets musical! We welcome our first guest, musical genius Meg Logue, who has arranged and performed potentially the most melodious cover ever of The Ballad of Persse O'Reilly. We discuss gravelly voiced Irishmen, German opera, singing at wakes, and agree that we'd all like a sip of whatever Poolbeg's on. This week's readers: Meg Logue, Toby Malone Progress: 47 pages complete, 581 pages to go; 7.4% read. For early drops, community and show notes, join us at our free Patreon, at ⁠⁠⁠⁠⁠patreon.com/wakepod⁠⁠⁠⁠⁠. We welcome comments from everyone: even, nay, especially, the dreaded purists. Come and "um actually" us!

We spoke to travel editor Eoghan Corry about the implications for Red Bull after they sent three skydivers in between the Poolbeg Towers at wind speeds of 253 km/h.

Emma Gilleece, Architectural Historian.

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. #PoolbegPharma, #POLB001, #Immunomodulator, #USPatentOffice, #IntellectualProperty, #Pharmaceuticals, #CytokineStorm, #Hypercytokinemia, #PatentGranted, #DrugDevelopment, #MedicalInnovation, #CancerImmunotherapy, #InfluenzaTreatment, #PharmaIndustry, #JohnMcEvoy, #HealthcareNews, #Biotech, #ClinicalTrials, #PharmaPartnerships, #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Jeremy Skillington, CEO of Poolbeg Pharma (POLB) talks Vox Markets through a landmark year that has seen the innovative biopharma company make huge strides progressing its treatments, opening up new markets, and strengthening its team - all whilst retaining its strong balance sheet thanks to disciplined capital allocation.

Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulcers in patients with Behçet's disease, a rare and debilitating condition. Skillington said the move is aligned with Poolbeg's strategic focus on rare and orphan diseases. Coté, with an extensive background in orphan drug approvals from his time at the FDA, highlighted the potential of the drug given its unique formulation and unmet need in the market. He explained the severe impact of Behçet's disease, underscoring the innovative potential of their topical treatment in improving the quality of life for those affected. Both CEO expressed optimism about their collaboration's potential to fast-track this novel treatment to market, leveraging Poolbeg's and Silk Road's combined expertise. Furthermore, Skillington provided insights into Poolbeg's financial health and strategic developments over the past year, mentioning a robust cash position of £12.2 million at the end of 2023. He emphasised the company's disciplined capital allocation and the expansion of its intellectual property portfolio. Looking ahead, Skillington outlined Poolbeg's focus on progressing its pipeline, particularly ongoing projects like POLB001 in the oncology sector, addressing cytokine release syndrome—a critical side effect in cancer immunotherapies. #PoolbegPharma, #SilkRoadTherapeutics, #orphanDrug, #BehçetsDisease, #PROG001, #cytokineReleaseSyndrome, #pharmaceuticals, #drugDevelopment, #orphanDiseases, #clinicalTrials, #FDA, #drugApproval, #healthcare, #medicalInnovation, #patientCare, #biotech, #pharma, #strategicPartnership, #marketAccess, #intellectualProperty, #capitalAllocation Headlines: New Topical Treatment for Behçet's Disease in Development by Poolbeg and Silk Road Exciting Developments in Rare Disease Treatment: Poolbeg Pharma's Latest Updates #ProactiveInvestors #InsertCompanyName #InsertStockMarket LEAVE THESE IN AS STANDARD & ADD ANY YOU FEEL ARE RELEVENT #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

As the Biologist, Researcher and two-time Pulitzer Prize winner, Edward Osborne Wilson stated, “In our attempt to make scientific discoveries every problem is an opportunity and the more difficult the problem the greater will be the importance of its solution”. With that in mind welcome to this latest episode in the Investing Matters podcast series with the hugely talented and globally respected, Dr. Jeremy Skillington, the Scientist, Biotechnologist, Entrepreneur and CEO of London AIM listed, £50 million market cap Poolbeg Pharma. Poolbeg Pharma plc is a biopharmaceutical company that is engaged in the development of medicines to address the unmet need for infectious and other prevalent diseases. The Company is involved in the development of a range of pharmaceutical products. Its product pipeline includes POLB 001, POLB 001 Oncology, POLB 001 Influenza, AI Programs, Oral GLP-1R Agonist. Its POLB 001 aims to target the Cytokine Release Syndrome (CRS) associated with many cancer immunotherapy treatments which impacts 70% of patients undergoing CAR T or Bispecific Antibody therapy. The company uses artificial intelligence to identify infectious disease drug targets & treatments. Its Oral GLP-1R Agonist is a delivery system which offers a scalable, natural, Generally Regarded As Safe (GRAS) approved solution for the oral delivery of metabolic peptide cargo to specific areas of the gut and into systemic circulation for the treatment of diabetes, obesity and other metabolic diseases. Jeremy whose father worked at a Pfizer manufacturing plant in Cork, Ireland, “Always had an interest in the sciences”. Which would first take him to Munster Technical University where he attained his Diploma in Food Science and Technology, followed by his Biochemistry, Bachelor of Science Degree with Honours from the University of Galway (UoG). He also later attained his Biochemistry PhD from UoG. After completing his PhD Jeremy did Postdoctoral research at the University of California, San Francisco for three years before entering the Biotech industry in the Business Development group at Genentech in California in 2002. Throughout his time at Genetech up to 2009 Jeremy played a significant role in executing over forty licensing, investment and collaborations with biotech companies globally. Jeremy recalls, “how he learned so much from this hard-working, driven, smart but friendly and supportive Genetech Business Development team. With two stand out people in those early days, being his hiring manager, Dr Jonathan Lewis, an Oxford educated Immunologist and investment banker, and an industry veteran, Dr Jack Obijeski. Who both took him under their wings and showed him the biotech ropes. Since returning to Ireland in 2009, Dr Jeremy Skillington has crammed in an awful lot globally, including investing in the Medtech space, being the third employee of the very significant Irish biotech firm Inflazome, which after a mere four years achieved a landmark exit in September 2020 when it was purchased by Swiss drug giant Roche, This after Inflazome's leadership team with Jeremy heading up its business development had driven its phenomenal success. Then in 2021 he took “the call“ from seasoned serial entrepreneur Cathal Friel to become the CEO of Poolbeg Pharma. Jeremy has held that role since mid-2021 prior to Poolbeg Pharma's AIM listing in July 2021. Dr Jeremy Skillington, CEO of Poolbeg Pharma now has over twenty-one years' experience in the biotech industry, please listen to his fascinatingly insightful Investing Matters interview. As he shares insights on the global and Irish MedTech, Pharma, Biotech industry, angel investing via the Medtech Syndicate, the importance having “skin in the game”, leading and investing his money into Poolbeg Pharma's long-term potential, due to its world class leadership team and robust pipeline of innovative products and much more.

Cathal Friel a serial entrepreneur having started hVIVO and Poolbeg pharma. His latest venture European Green Transition floated on the AIM stock market in London yesterday and values the company at around €17m.EGT hopes to find rare Earth metals which can be used to transition away from fossil fuels. Cathal joined Joe in studio this morning to chat about his latest venture.

Jeremy Skillington and David Allmond of Poolbeg Pharma, discuss with David Buik about the company's journey, market position, and future prospects. They touch upon Poolbeg's establishment, market performance, recent developments, strategic focus on rare diseases, and utilisation of artificial intelligence in drug development. The conversation also delves into Poolbeg's unique offerings, such as its oral delivery programs and differentiation in the competitive landscape of biopharma.

hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while emphasizing his commitment to remain a long-term, supportive shareholder despite this sale. Friel, who co-founded hVIVO (formerly known as Open Orphan) in 2017, highlighted the company's significant growth and his active involvement in its operations and strategic direction. He mentioned his 25-year experience in mergers and acquisitions (M&A) and his confidence in the company's ability to surpass its medium-term revenue target of £100 million, partly through strategic M&A activities. Additionally, Friel talked about his new role as Executive Chairman at Poolbeg, a company associated with hVIVO, assuring that this would not diminish his involvement with hVIVO. He shared his enthusiasm for the future of both companies, underscoring his role in identifying market opportunities and assembling high-performing teams to capitalize on them. #hVIVO #PoolbegPharma #CathalFriel #PharmaInvesting #Biotech #MergersAndAcquisitions #InvestmentBanking #HealthcareInnovation #StockMarket #Pharmaceuticals #ExecutiveLeadership #GrowthStrategy #ShareholderValue #BiotechStocks #InvestmentOpportunities #PharmaNews #UKBiotech #StrategicGrowth #InvestorRelations #CorporateStrategy #HealthcareStocks #proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another company he founded. With the addition of key former Amryt leadership team members to Poolbeg, Friel said he is optimistic about the company's aggressive growth prospects and is focused on share price appreciation. The chairman also explained the rational for the sale of shares in hVIVO PLC by directors, including himself. Friel, who has a rich background in mergers and acquisitions (M&A) and investment banking, said the decision was driven by strong institutional demand for hVIVO stock. Despite selling a small portion of his stake, he affirmed his long-term commitment to the company, highlighting its robust growth, profitability, and cash generation under current management. He also revealed plans to increase his stake in Poolbeg, indicating confidence in the company's potential and his commitment to driving shareholder value. #PoolbegPharma #CathalFriel #PharmaInvesting #Biotech #MergersAndAcquisitions #InvestmentBanking #HealthcareInnovation #StockMarket #Pharmaceuticals #ExecutiveLeadership #GrowthStrategy #ShareholderValue #BiotechStocks #InvestmentOpportunities #PharmaNews #UKBiotech #StrategicGrowth #InvestorRelations #CorporateStrategy #HealthcareStocks #proactiveinvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma Plc chief business officer David Allmond joined Proactive's Stephen Gunnion with details of independent research that confirms the massive market potential for Poolbeg's POLP 001 in cancer immunotherapies. This asset is being explored for its ability to potentially prevent or treat cytokine release syndrome (CRS), a significant side effect of cancer immunotherapies. With the cancer immunotherapy market expected to reach $140 billion by 2030, POLB 001 presents an over $10 billion opportunity if successful. Additionally, Allmond elaborated on Poolbeg's increasing emphasis on rare and orphan diseases, leveraging its ongoing programs in influenza with POLB 001, obesity, metabolic conditions, and AI-driven discovery for novel targets. The company is actively considering strategies to acquire near-stage commercial or in-market products in this high unmet need, limited competition sector. This approach aligns with Poolbeg's evolution towards a commercial-stage organization, aiming to generate revenue and continue its growth trajectory. Furthermore, Allmond explained how POLB 001 fits into the rare orphan disease space, given its potential applications in orphan cancers where immunotherapies have shown success. Poolbeg's strategic pivot towards rare and orphan diseases complements its existing portfolio, aiming for a dual-track growth strategy focusing on both its current programs and commercial opportunities in the rare and orphan disease market. ‌ #PoolbegPharma #CancerImmunotherapy #RareDiseases #OrphanDiseases #Biotech #HealthcareInnovation #MedicalResearch #Pharmaceuticals #CytokineReleaseSyndrome #Immunotherapy #Biopharmaceuticals #DrugDevelopment #ClinicalTrials #PULP001 #DavidAllmond #ProactivInterview #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

The ESB has opened a major battery plant at its Poolbeg site in Dublin which will add 75MW (150MWh) of fast-acting energy storage to help provide grid stability and deliver more renewables on Ireland's electricity system. This latest battery energy storage system (BESS), currently the largest site of its kind in commercial operation in Ireland, is part of ESB's pipeline of projects which are being delivered at sites in Dublin and Cork - representing an investment of up to €300m. These high-capacity batteries can store excess renewable energy for discharge when required, and in doing so, help to support Ireland in reaching its ambitious climate targets by 2030 and ESB in achieving its Net Zero by 2040 strategy. This project, operational since late November 2023, has a capability of providing 75MW of energy for two hours to Ireland's electricity system. This plant is located at ESB's Poolbeg Energy Hub in Dublin where some of the latest technologies that will support the future delivery of renewable energy including batteries, hydrogen and offshore wind will be deployed over the next decade. ESB is working with partners Fluence, as well as Irish companies, Kirby Group and Powercomm Group, in the delivery of these projects at Poolbeg, Aghada, Inchicore, and South Wall - the remainder of these projects are due to be completed this year. Eamon Ryan TD, Minister for the Environment, Climate and Communications, said: "Energy storage like this major battery plant at the ESB's flagship site in Poolbeg will be a core part of Ireland's new renewable energy transition and will play a key role in balancing our new, homegrown power supply. No electricity system can operate without a backup. In Ireland this has traditionally been provided by fossil fuel generation. Jim Dollard, ESB Executive Director, Generation and Trading, outlined how the plant will support ESB's Net Zero by 2040 target: "Today marks another important milestone for ESB as we launch our latest fast-acting grid-scale battery unit that will support grid stability and help to deliver more renewables on Ireland's electricity system. The location of this project, at our Poolbeg Energy Hub, will build on our longstanding history of innovation at the site. See more stories here.

Poolbeg Pharma PLC's newly appointed Vice President of Clinical Operations Laura Maher joined Proactive's Stephen Gunnion to discuss her role at the company. Maher detailed her responsibilities at Poolbeg, emphasizing her leadership in developing and managing clinical programs. She highlighted the importance of collaborations, both internally and with external service providers, to ensure the acquisition of quality data. Maher's significant achievements at Amryt include her pivotal role in the development and approval of Filsuvez, a treatment for Epidermolysis Bullosa (EB). She oversaw the largest-ever EB trial, leading to EMA approval in June 2022, marking it as the world's first approved treatment for EB. Despite initial FDA rejection, her perseverance led to eventual FDA approval in December 2023. Her extensive background in clinical research and operations, beginning with a research master's degree and experience in various roles across academia and small pharma companies, informs her approach at Poolbeg. Maher expressed her enthusiasm for working in a dynamic environment like Poolbeg, particularly excited about their cancer immunotherapy and cytokine release syndrome projects. #PoolbegPharma #ClinicalOperations #LauraMaher #PharmaceuticalIndustry #ClinicalTrials #DrugApproval #EpidermolysisBullosa #EBTreatment #FDAApproval #EMAAuthorization #AmrikPharma #Philserv #HealthcareInnovation #CancerImmunotherapy #CytokineReleaseSyndrome #PharmaLeadership #ClinicalResearch #DrugDevelopment #PharmaNews #ProactiveLondon #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) Chief Legal Officer John McEvoy speaks to Thomas Warner from Proactive London about how he intends to carry out his new role, having joined Poolbeg on January 1st. McEvoy details his transition from commercial-stage pharmaceutical company Amryt Pharma, saying that he was drawn to Poolbeg's potential for growth and innovation. His decision was influenced by previous encounters with Poolbeg's leadership team, notably Chairman Cathal Friel, and the company's promising pipeline, including its POLB 001 oncology asset. McEvoy's tenure at Amryt was marked by significant accomplishments, including a $1.5 billion valuation and his recognition as Life Sciences Lawyer of the Year in 2023. He says his experience in guiding a high-growth, NASDAQ-listed company and expertise in multiple legal jurisdictions played a pivotal role in his success. At Poolbeg, McEvoy aims to leverage his diverse legal background and strategic insight to drive the company's growth. He emphasises the importance of a holistic approach as a Chief Legal Officer, contributing not just legal expertise but also strategic guidance and leadership across the organisation. McEvoy's focus will be on developing Poolbeg's intellectual property portfolio and exploring market opportunities for the company's assets, with an eye on near-term revenue generation and pipeline expansion. #PoolbegPharma #JohnMcEvoy #PharmaceuticalIndustry #Biotech #LegalLeadership #PharmaInnovation #DrugDevelopment #OncologyResearch #LifeSciences #BiopharmaGrowth #PharmaPipeline #PharmaStrategy #HealthcareLeadership #CorporateLaw #IntellectualProperty #MarketExpansion #Pharmaceuticals #LegalInsights #ExecutiveInterview #BusinessStrategy #HealthcareIndustry #PharmaLeadership #BiotechInnovation #PharmaTrends #HealthcareTrends #PharmaceuticalLaw #ProactiveInvestors #pharma #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company announced some progress on lead asset, POLB 001. Skillington, fresh from the JPMorgan conference in San Francisco, announces "very positive" in vivo data for POLB 001, showing efficacy in reducing cancer immunity-induced cytokine release syndrome (CRS). This development bolsters the company's hypothesis and strengthens their patent applications in this area. Skillington highlighted POLB 001's dual role as both a preventative and a treatment for CRS, a notable advancement since no approved preventative therapies currently exist for this condition. This development could significantly benefit patients and ease healthcare system burdens. With its potential as an oral therapy, POLB 001 stands out in a market dominated by injectable treatments, offering the convenience of at-home administration. Further enhancing Poolbeg's strategic position, the addition of David Allmond as Chief Business Officer and the formation of a scientific advisory board have provided valuable insights for program positioning and market needs. Finally, Skillington discusses the immense market potential for POLB 001, estimating it at $1 billion, particularly in treating multiple myeloma, high-grade lymphoma, and acute lymphoblastic leukemia. #PoolbegPharma #JeremySkillington #HealthcareInnovation #CancerTreatment #Immunotherapy #POLB001 #CytokineReleaseSyndrome #PharmaceuticalIndustry #BiotechNews #MedicalResearch #ProactivInterview #CancerTherapyAdvancements #HealthTech #PharmaLeaders #Biotechnology #Oncology #PharmaNews #MedicalBreakthrough #ClinicalTrials #HealthcareTrends #InnovativeMedicine #ProactiveInvestors #poolbeg #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

(Watch the video interview HERE) Vox Markets talks to Poolbeg Pharma #POLB CEO Jeremy Skillington and Chief Business Office David Allman about the latest positive results for its lead asset POLB 001 which could help it tap into what could be a $1bn market opportunity in cancer immunotherapy. 0:30 How the latest in vivo trial results strengthens and facilitates the extension of patent applications for POLB 001 in cancer immunotherapy-induced CRS 1:36 The significance of the potential for POLB 001 to be delivered as an oral therapy to allow use in an outpatient setting 3:12 How an Independent Advisory Board is supportive of POLB 001's potential to both prevent and treat cancer immunotherapy-induced CRS. 5:02 Why the stated $1bn market opportunity in only three cancer types could be the tip of the iceberg

Poolbeg Pharma #POLB CEO Jeremy Skillington talks to Vox Markets about a year which has seen the global pharma industry take a keen interest in the company's innovative AI-led approach.

(Watch the video interview HERE) Jeremy Skillington, CEO of Poolbeg Pharma #POLB, talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates 00:28 Details of the latest results of lab-based analysis of RSV drug candidates. 01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery. 2:41 The importance of the data quality offered by human challenge models in lab-base analysis. 4:35 The growing importance of AI in drug discovery, and how Poolbeg's leading position should open up partnering opportunities with biopharma groups.

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on clinical-stage biopharmaceutical company Poolbeg Pharma. Appiah starts by explaining the scale of the opportunity that Poolbeg is pursuing with its lead compound POLB001 in acute influenza, noting the estimated 3-5 million severe influenza cases globally per annum. The company is broadening its reach by expanding the compound into the oncology sector. Additionally, Appiah highlights Poolbeg's recent developments in the oral vaccine sector. The company's oral delivery platform is in the limelight following an announcement about their collaboration with an undisclosed NASDAQ-listed biopharma enterprise. The partnership aims to utilise Poolbeg's oral drug delivery technology to optimise drug formulations targeting metabolic conditions. Significantly, this venture could pave the way for Poolbeg to tap into the burgeoning market for GLP-1 injectable treatments for obesity and diabetes, which is expected to grow significantly in the coming years. For a comprehensive insight into Poolbeg Pharma PLC, Daniel Appiah's full research report is accessible via the link in the video. #DanielAppiah #PoolbegPharma #ProactiveResearch #Immunomodulator #CytokineReleaseSyndrome #SevereInfluenza #OncologyTreatments #OralVaccine #OralDrugDelivery #BiopharmaCollaboration #GLP1Treatments #ObesityTreatment #DiabetesTreatment #ProactiveInvestors #poolbeg #polb #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Jeremy Skillington CEO of Poolbeg Pharma #POLB discusses their partnership with Nasdaq-Listed Biopharma company for the development of an optimised oral drug to treat a metabolic condition. Under the agreement, the Company will receive funding to work with its new partner to produce a prototype drug utilising Poolbeg's licensed oral delivery technology.

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech company has signed a new collaboration agreement with an unspecified NASDAQ-listed biopharma company. He explains that the collaboration is aimed at developing an optimized oral drug for metabolic conditions, with Poolbeg receiving funding to produce a prototype drug encapsulating one of the partner's drugs for the same condition. The focus is on improving drug delivery and achieving the ideal site of action, which could enhance efficacy and safety. Skillington expresses optimism about the collaboration potentially evolving into a full licensing agreement, highlighting the goal of generating early revenues for Poolbeg. The partnership's core attraction lies in Poolbeg's validated encapsulation technology, which is believed to enhance the partner's products' bioavailability and effectiveness. The CEO emphasises the significance of delivering drugs to their ideal site of action, particularly for metabolic diseases. By targeting the drug orally to the precise location of action, it can lead to reduced dosage requirements and improved safety. He says that Poolbeg continues to work on various initiatives, including the orange GLP-1 program and an oral vaccine program funded by the Irish government. The move towards oral delivery aims to enhance convenience for patients and expand the company's reach beyond traditional injectable treatments. #PoolbegPharma #BiopharmaCollaboration #OralDrugDevelopment #MetabolicConditions #DrugDeliveryTechnology #LicensingAgreement #Bioavailability #IdealSiteOfAction #Efficacy #SafetyImprovement #PatientConvenience #GLP1Program #OralVaccine #PharmaceuticalInnovation #HealthcareNews #MedicalAdvancements #BiotechIndustry #JeremySkillington #NASDAQPartner #IrishPharmaceuticals #DrugResearch #ClinicalTrials #InnovationInMedicine #PharmaNews #MedicalBreakthroughs #ProactiveInvestors #InsertCompanyName #InsertStockMarket LEAVE THESE IN AS STANDARD & ADD ANY YOU FEEL ARE RELEVENT #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Jeremy Skillington CEO of Poolbeg Pharma: "During H1 2023, we made significant progress in advancing our pipeline, bolstered by the strong clinical trial data for POLB 001 and breakthroughs in our AI-led drug discovery programmes. We are well positioned for ongoing development and future growth with a strong focus on our business development activities." Interim Results Highlights and Business Update ·    Strong cash balance of £14.1 million as at 30 June 2023 (31 December 2022: £16.2m) ·    Positive results from the POLB 001 LPS human challenge trial. The asset has the potential to be an effective treatment for severe influenza and potentially other acute inflammatory conditions ·    Strategic expansion of POLB 001 into oncology, including as a potential treatment option for Cytokine Release Syndrome (CRS), a side-effect associated with up to 95% of CAR T cell therapies ·    Further to discussions with prospective partners interested in this area, the Company is actively exploring a potential new indication for POLB 001 in oncology beyond CAR T   ·    The Company's artificial intelligence (AI) programme with CytoReason provided unparalleled insights into influenza infection and successfully identified a number of novel and valuable drug targets ·    The lab-based validation of the Respiratory Syncytial Virus (RSV) drug targets and treatments identified from the Company's AI-led programme is progressing and expected to complete in H2 2023 ·    The Poolbeg-led Oral Vaccine consortium (EncOVac), which was awarded €2.3 million in grant funding, progressed to the next phase of development, marked by the commencement of the encapsulation validation process ·    Continued progress on the Oral GLP-1 agonist proof-of-technology clinical trial preparation. As a result of adopting recommendations from a number of Key Opinion Leaders (KOLs), the clinical trial design has been refined and the trial is expected to commence in H1 2024 ·    Industry veteran, Professor Brendan Buckley, appointed as Non-Executive Director in May 2023 To read the full RNS click here

(Watch the video interview HERE) Jeremy Skillington, CEO of Poolbeg Pharma (POLB ), talks us through the results of its successful collaboration with leading AI specialist CytoReason, making at a pioneer in AI-enabled drug discovery. 0:28 Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg's POLB001 treatment. 2:07 How the approach to analyse human challenge data for influenza with AI is the first of its kind. 3:28 Next steps after the successful conclusion of the collaboration, moving towards partnership. 4:54 Why Poolbeg is at the forefront of AI-enabled drug discovery

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year."

Dr. Jeremy Skillington, Chief Executive Officer of Poolbeg Pharma #POLB provides an update on the company's led EncOVac Consortium Oral Vaccine Programme, which he says is a key step in the creation of a Phase I clinical trial ready oral vaccine candidate To read the full RNS click here

For many private European biotechs, flat or down valuations have become the new normal as they struggle to raise money despite having quality science, +ND Capital's Dani Bach said on a special edition of the BioCentury This Week podcast featuring takeaways from the 2023 Bio€quity Europe conference in Dublin. Investors, he said, are flocking to a handful of outsize fundraising rounds out of fear. In conversation Monday with Jeff Cranmer and Stephen Hansen of BioCentury and Poolbeg's Jeremy Skillington, Bach described a bipolar fundraising environment in which the “bulk of companies are struggling for money and a few are getting massive amounts of money even beyond their wild expectations.” Bach, Skillington and BioCentury's editors also discuss Ireland's burgeoning biotech ecosystem, Europe's biopharma hubs and the performance of U.K.'s biotechs listed on the London Stock Exchange. This episode is sponsored by Jeito Capital.

Poolbeg Pharma (OTCQB: POLBF) is a clinical stage infectious disease pharmaceutical company with a capital light clinical model which is looking to develop multiple products faster and more cost effectively than the conventional biotech model. CEO Jeremy Skillington joins us to discuss how the Covid-19 pandemic has impacted the company's research on infectious diseases. View Podcast Transcript for Poolbeg Pharma